Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men*
- 17 March 2015
- journal article
- research article
- Published by CSIRO Publishing in Sexual Health
- Vol. 12 (3) , 240-248
Abstract
Background: Although it significantly improves HIV-related outcomes, some components of combination antiretroviral therapy (ART) cause lipodystrophy syndrome. The composition of combination ART has changed over time but the impact on lipodystrophy prevalence is unknown. Methods: One hundred HIV-infected males underwent dual-energy X-ray absorptiometry scanning, serum lipid testing and completed a questionnaire in a cross-sectional study in 2010. Thirty-four participants of a 1998 study cohort were re-evaluated in 2010. The same parameters were used to define and compare lipodystrophy, metabolic syndrome and cardiovascular disease (CVD) risk in the two time periods. Results: In 2010, the prevalence of lipodystrophy was lower when compared with 1998 (53% v. 69%, P = 0.012), despite higher mean age (51.8 v. 42.1 years, P < 0.0001), duration of HIV (165 v. 86 months, P < 0.0001), ART exposure (129 v. 38 months, P < 0.0001), CD4+ cell count (601 v. 374 cells µL-1, P < 0.0001) and waist circumference (95.5 v. 89.9 cm P < 0.0001). Cholesterol (5.0 v. 5.6 mmol L-1, P = 0.0001) and triglycerides (1.9 v. 3.7 mmol L-1, P < 0.0001) were significantly lower in 2010. Factors associated with an increased risk of lipodystrophy in 2010 were duration of HIV infection and low-density lipoprotein cholesterol, whereas current tenofovir or abacavir use was associated with a decreased risk of lipodystrophy. On multivariate analysis low-density lipoprotein cholesterol (OR, 2.65; CI, 1.4–4.9) remained significant for an increased risk and current tenofovir or abacavir use with reduced risk of lipodystrophy (OR, 0.096; CI, 0.011–0.83). In 2010 there was a higher prevalence of metabolic syndrome (33 v. 28%) and higher median Framingham CVD risk (9.9% (5.7–14.6) v. 8.2% (4.5–12.9). Conclusion: Despite ageing and longer duration of HIV infection and ART exposure, the prevalence of lipodystrophy in HIV-infected men significantly declined over a 12-year period. However, a trend exists toward a higher prevalence of metabolic syndrome and increased CVD risk.Keywords
This publication has 28 references indexed in Scilit:
- Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study*HIV Medicine, 2011
- Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbiditiesJournal of Antimicrobial Chemotherapy, 2009
- Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected IndividualsDiabetes Care, 2009
- Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006HIV Medicine, 2008
- Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapyAIDS, 2007
- Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavirAIDS, 2004
- Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL StudyClinical Infectious Diseases, 2004
- Monitoring of long-term toxicities of HIV treatmentsAIDS, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Human Body Composition and the Epidemiology of Chronic DiseaseObesity Research, 1995